295 related articles for article (PubMed ID: 25371149)
1. Persistence of DNMT3A mutations at long-term remission in adult patients with AML.
Pløen GG; Nederby L; Guldberg P; Hansen M; Ebbesen LH; Jensen UB; Hokland P; Aggerholm A
Br J Haematol; 2014 Nov; 167(4):478-86. PubMed ID: 25371149
[TBL] [Abstract][Full Text] [Related]
2. DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.
El Ghannam D; Taalab MM; Ghazy HF; Eneen AF
Blood Cells Mol Dis; 2014; 53(1-2):61-6. PubMed ID: 24512939
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
[TBL] [Abstract][Full Text] [Related]
4. Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia.
Berenstein R; Blau IW; Suckert N; Baldus C; Pezzutto A; Dörken B; Blau O
J Exp Clin Cancer Res; 2015 May; 34(1):55. PubMed ID: 25994761
[TBL] [Abstract][Full Text] [Related]
5. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
Thol F; Damm F; Lüdeking A; Winschel C; Wagner K; Morgan M; Yun H; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Kanz L; Fiedler W; Kirchner H; Heil G; Krauter J; Ganser A; Heuser M
J Clin Oncol; 2011 Jul; 29(21):2889-96. PubMed ID: 21670448
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia.
Marková J; Michková P; Burčková K; Březinová J; Michalová K; Dohnalová A; Maaloufová JS; Soukup P; Vítek A; Cetkovský P; Schwarz J
Eur J Haematol; 2012 Feb; 88(2):128-35. PubMed ID: 21967546
[TBL] [Abstract][Full Text] [Related]
7. Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.
Bhatnagar B; Eisfeld AK; Nicolet D; Mrózek K; Blachly JS; Orwick S; Lucas DM; Kohlschmidt J; Blum W; Kolitz JE; Stone RM; Bloomfield CD; Byrd JC
Br J Haematol; 2016 Oct; 175(2):226-236. PubMed ID: 27476855
[TBL] [Abstract][Full Text] [Related]
8. Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations.
Devillier R; Gelsi-Boyer V; Brecqueville M; Carbuccia N; Murati A; Vey N; Birnbaum D; Mozziconacci MJ
Am J Hematol; 2012 Jul; 87(7):659-62. PubMed ID: 22535592
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of DNMT3A mutations in patients with acute myeloid leukemia.
Ibrahem L; Mahfouz R; Elhelw L; Abdsalam EM; Soliman R
Blood Cells Mol Dis; 2015 Jan; 54(1):84-9. PubMed ID: 25172541
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications of
Tan M; Ng IKS; Chen Z; Ban K; Ng C; Chiu L; Seah E; Lin M; Tai BC; Yan B; Ng CH; Chng WJ
J Clin Pathol; 2017 Aug; 70(8):669-676. PubMed ID: 28100593
[TBL] [Abstract][Full Text] [Related]
11. Distribution of mutations in DNMT3A gene and the suitability of mutations in R882 codon for MRD monitoring in patients with AML.
Jeziskova I; Musilova M; Culen M; Foltankova V; Dvorakova D; Mayer J; Racil Z
Int J Hematol; 2015 Nov; 102(5):553-7. PubMed ID: 26290145
[TBL] [Abstract][Full Text] [Related]
12. Two novel methods for rapid detection and quantification of DNMT3A R882 mutations in acute myeloid leukemia.
Mancini M; Hasan SK; Ottone T; Lavorgna S; Ciardi C; Angelini DF; Agostini F; Venditti A; Lo-Coco F
J Mol Diagn; 2015 Mar; 17(2):179-84. PubMed ID: 25554589
[TBL] [Abstract][Full Text] [Related]
13. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.
Guryanova OA; Shank K; Spitzer B; Luciani L; Koche RP; Garrett-Bakelman FE; Ganzel C; Durham BH; Mohanty A; Hoermann G; Rivera SA; Chramiec AG; Pronier E; Bastian L; Keller MD; Tovbin D; Loizou E; Weinstein AR; Gonzalez AR; Lieu YK; Rowe JM; Pastore F; McKenney AS; Krivtsov AV; Sperr WR; Cross JR; Mason CE; Tallman MS; Arcila ME; Abdel-Wahab O; Armstrong SA; Kubicek S; Staber PB; Gönen M; Paietta EM; Melnick AM; Nimer SD; Mukherjee S; Levine RL
Nat Med; 2016 Dec; 22(12):1488-1495. PubMed ID: 27841873
[TBL] [Abstract][Full Text] [Related]
14. Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission.
Sun Y; Shen H; Xu T; Yang Z; Qiu H; Sun A; Chen S; Wu D; Xu Y
Leuk Res; 2016 Oct; 49():102-7. PubMed ID: 27626217
[TBL] [Abstract][Full Text] [Related]
15. Influence of DNMT3A R882 mutations on AML prognosis determined by the allele ratio in Chinese patients.
Yuan XQ; Chen P; Du YX; Zhu KW; Zhang DY; Yan H; Liu H; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Yang J; Zeng WJ; Chen XP
J Transl Med; 2019 Jul; 17(1):220. PubMed ID: 31291961
[TBL] [Abstract][Full Text] [Related]
16. DNMT3A mutation is a poor prognosis biomarker in AML: results of a meta-analysis of 4500 AML patients.
Shivarov V; Gueorguieva R; Stoimenov A; Tiu R
Leuk Res; 2013 Nov; 37(11):1445-50. PubMed ID: 23962568
[TBL] [Abstract][Full Text] [Related]
17. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.
Shlush LI; Zandi S; Mitchell A; Chen WC; Brandwein JM; Gupta V; Kennedy JA; Schimmer AD; Schuh AC; Yee KW; McLeod JL; Doedens M; Medeiros JJ; Marke R; Kim HJ; Lee K; McPherson JD; Hudson TJ; ; Brown AM; Yousif F; Trinh QM; Stein LD; Minden MD; Wang JC; Dick JE
Nature; 2014 Feb; 506(7488):328-33. PubMed ID: 24522528
[TBL] [Abstract][Full Text] [Related]
18. DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia.
Sehgal AR; Gimotty PA; Zhao J; Hsu JM; Daber R; Morrissette JD; Luger S; Loren AW; Carroll M
Clin Cancer Res; 2015 Apr; 21(7):1614-20. PubMed ID: 25609058
[TBL] [Abstract][Full Text] [Related]
19. DNMT3A intragenic hypomethylation is associated with adverse prognosis in acute myeloid leukemia.
Zhang YY; Yao DM; Zhu XW; Zhou JD; Ma JC; Yang J; Wen XM; Guo H; Lin J; Qian J
Leuk Res; 2015 Oct; 39(10):1041-7. PubMed ID: 26242829
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of DNMT3a gene mutations in acute myelogenous leukemia].
Qiao C; Sun C; Zhang SJ; Qian SX; Qian XF; Miao KR; Zhu HY; Hong M; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):303-7. PubMed ID: 21518476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
